Charles Gore is the Executive Director of the Medicines Patent Pool (MPP). Following a career in patient representation and public health advocacy, he took up the post in July 2018 to guide MPP in its expansion into new areas covered by the WHO Essential Medicines List.
He was diagnosed with hepatitis C in 1995 and cirrhosis in 1998. In 2000 he set up The Hepatitis C Trust in the UK which he ran for 18 years. In 2002 he was treated and cured of the virus. He helped create the European Liver Patients Association and was its first President in 2004. In 2007 he established the World Hepatitis Alliance and was President until December 2017. As a result of advocacy by the Alliance, WHO adopted successive viral hepatitis resolutions in 2010, 2014 and 2016, culminating in endorsement of the goal of eliminating hepatitis B and C by 2030. In addition to direct advocacy with over 50 Ministries of Health, Charles led on advising countries on finding sustainable domestic financing for hepatitis programs. Charles also sat on a number of national and international advisory bodies including the WHO Director-General’s HIV and Hepatitis STAC and has been a member of all the WHO guideline development groups on testing and treating viral hepatitis.